Skip to main content

Table 8 Significant associations of placental target expression with taurine and tryptophan in fetal compartments

From: Fetal sex modulates placental microRNA expression, potential microRNA-mRNA interactions, and levels of amino acid transporter expression and substrates: INFAT study subpopulation analysis of n-3 LCPUFA intervention during pregnancy and associations with offspring body composition

   

Model 1

 

Model 2

 
 

Outcome

variables

N

beta

(95% CI)

P

beta

(95% CI)

P

mTOR

PL-Tau

40

255.92 (32.50; 479.34)

0.026

325.06 (77.33; 572.78)

0.012

UC-Tau

34

− 192.24 (− 478.48; 94.00)

0.181

−282.65 (−616.79; −51.49)

0.094

PL-Trp

40

1.10 (−0.14; 2.35)

0.080

1.46 (0.13; 2.80)

0.033

UC-Trp

34

26.65 (−14.84; 63.13)

0.200

27.86 (− 20.53; 76.24)

0.249

SLC7A5

PL-Tau

40

48.91 (−68.21; 166.03)

0.403

73.16 (−67.79; 214.11)

0.299

UC-Tau

34

65.27 (−82.22; 212.27)

0.374

83.33(−91.10; 265.75)

0.325

PL-Trp

40

0.23 (−0.41; 0.87)

0.467

0.54 (−0.16; 1.24)

0.125

UC-Trp

34

−11.12 (−32.34; 10.10)

0.294

−17.50 (−40.79; 5.80)

0.135

LAT1

PL-Tau

17

26.52 (−91.42; 144.45)

0.639

56.15 (−146.28; 258.58)

0.557

UC-Tau

16

194.53 (−17.01; 406.07)

0.069

476.02 (139.63; 812.42)

0.010

PL-Trp

17

0.13 (−0.76; 1.02)

0.760

0.03 (−1.39; 1.44)

0.968

UC-Trp

16

3.37 (−25.76; 32.50)

0.808

−30.45 (−75.29; 14.40)

0.163

  1. Linear regression analyses: summary of significant associations of mTOR mRNA, SLC7A5 mRNA and LAT1 protein with taurine (Tau) and tryptophan (Trp) is shown. ΔCq-values for mRNA and microRNA expression of respective genes were used; optical density values for LAT1 protein expression normalized to respective GAPDH protein from western blot experiments were used. Amino acid levels (μmol/g protein)-values were used for placental tissue (PL); plasma amino acid levels (μmol/L)-values were used for umbilical cord plasma (UC). Beta (95% CI) values with P-values < 0.05 are given in bold. Abbreviations: N Sample numbers analyzed, P P-value
  2. Model 1: unadjusted
  3. Model 2: adjusted for respective baseline levels of maternal Tau and Trp levels at week-15 of gestation (P15) before treatment, sex, and group